Surgeons should aim to prevent intraoperative femur fractures by identifying high-risk patients and surgical risk factors. Sound change during broaching is key to know when to stop. KOLOA ...

WEDNESDAY, Jan. 15, 2025 (HealthDay News) -- For early postmenopausal women, zoledronate administered at baseline and five years is effective for preventing morphometric vertebral fracture, according ...

Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate ...

Intra-Cellular Therapies ITCI signed a definitive agreement with pharma bigwig Johnson & Johnson JNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share ...

35 million participate in holy dip, says Uttar Pradesh chief minister Festival expected to boost economy by $30 billion-$35 billion PRAYAGRAJ, India, Jan 14 (Reuters) - Naked Hindu ascetics ...

Johnson & Johnson will acquire Intra-Cellular for $132 per share in cash, a 39 percent premium over Intra-Cellular's Friday closing price of $94.87. Following the announcement, shares of both ...

(AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central ...

“The biggest week was just I had a little transverse process fracture in my back [against the Raiders]. That week, [I] got treatment and kind of made it through that week. Monday Night ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

(RTTNews) - Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...

(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the ...

Johnson & Johnson has struck a $14.6bn deal to buy neuroscience drugmaker Intra-Cellular Therapies, the US pharmaceutical company said, marking the biggest biotech buyout in more than a year.